1225380-63-1

Basic information

• Product Name: 5-iodo-2-[(5-methyl-3-{3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl}-1H-pyrazol-1-yl)-methyl]pyridine
• Synonyms: 5-iodo-2-[(5-methyl-3-{3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl}-1H-pyrazol-1-yl)-methyl]pyridine
• CAS NO: 1225380-63-1
• Molecular Weight: 527.244
• Mol File: 1225380-63-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 5-iodo-2-[(5-methyl-3-{3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl}-1H-pyrazol-1-yl)-methyl]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-iodo-2-[(5-methyl-3-{3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl}-1H-pyrazol-1-yl)-methyl]pyridine(1225380-63-1)
• EPA Substance Registry System: 5-iodo-2-[(5-methyl-3-{3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl}-1H-pyrazol-1-yl)-methyl]pyridine(1225380-63-1)

Safety Data

• Hazardous Substances Data: 1225380-63-1(Hazardous Substances Data)

Upstream product

• 402-61-9 5-methyl-1H-pyrazole-3-carboxylic acid 
• 1085453-46-8 5-(5-methyl-1H-pyrazol-3-yl)-3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazole 
• 1225380-30-2 2-(chloromethyl)-5-iodopyridine 
• 116195-81-4 2,5-di-iodopyridine 
• 31181-83-6 2-(hydroxymethyl)-5-iodopyridine 

Downstream Products

• 1226860-98-5 1-[2-({6-[(5-Methyl-3-{3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl}-1H-pyrazol-1-yl)-methyl]pyridin-3-yl}amino)ethyl]piperidin-4-ol 

Relevant articles and documents

HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS

The present application relates to novel aryl compounds with heterocyclic substituents, processes for their preparation, their use for treatment and/or prevention of diseases and their use for the preparation of medicaments for treatment and/or prevention

HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS

The present application relates to novel substituted aryl compounds, processes for their preparation, their use for treatment and/or prevention of diseases and their use for the preparation of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be carried out as monotherapy or also in combination with other medicaments or further therapeutic measures.